Redmile 13F annual report
Redmile is an investment fund managing more than $2.72 trillion ran by Jennifer Ciresi. There are currently 77 companies in Mrs. Ciresi’s portfolio. The largest investments include Krystal Biotech Inc and Amicus Therapeutics Inc, together worth $425 billion.
$2.72 trillion Assets Under Management (AUM)
As of 8th May 2024, Redmile’s top holding is 1,508,250 shares of Krystal Biotech Inc currently worth over $268 billion and making up 9.8% of the portfolio value.
Relative to the number of outstanding shares of Krystal Biotech Inc, Redmile owns less than approximately 0.1% of the company.
In addition, the fund holds 13,257,286 shares of Amicus Therapeutics Inc worth $156 billion, whose value fell 12.5% in the past six months.
The third-largest holding is Immunome worth $121 billion and the next is Scholar Rock Hldg Corp worth $114 billion, with 6,419,610 shares owned.
Currently, Redmile's portfolio is worth at least $2.72 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Redmile
The Redmile office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Jennifer Ciresi serves as the General Counsel and Chief Compliance Officer at Redmile.
Recent trades
In the most recent 13F filing, Redmile revealed that it had opened a new position in
Immunome and bought 4,889,554 shares worth $121 billion.
This means they effectively own 0.4% of the company.
Immunome makes up
5.8%
of the fund's Health Care sector allocation and has grown its share price by 148.9% in the past year.
The investment fund also strengthened its position in Scholar Rock Hldg Corp by buying
3,015,684 additional shares.
This makes their stake in Scholar Rock Hldg Corp total 6,419,610 shares worth $114 billion.
On the other hand, there are companies that Redmile is getting rid of from its portfolio.
Redmile closed its position in Seagen Inc on 15th May 2024.
It sold the previously owned 854,013 shares for $151 million.
Jennifer Ciresi also disclosed a decreased stake in Krystal Biotech Inc by 0.2%.
This leaves the value of the investment at $268 billion and 1,508,250 shares.
One of the largest hedge funds
The two most similar investment funds to Redmile are Sigfig Wealth Management and Silicon Valley Community Foundation. They manage $2.72 trillion and $2.73 trillion respectively.
Jennifer Ciresi investment strategy
Redmile’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 76.1% of
the total portfolio value.
The fund focuses on investments in the United States as
63.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
12% of the total holdings value.
On the other hand, small-cap stocks make up only 2.6% of the portfolio.
The average market cap of the portfolio companies is close to $10.7 billion.
The complete list of Redmile trades based on 13F SEC filings
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Krystal Biotech Inc |
20.56%
1,508,250
|
$268,362,923,000 | 9.85% |
| Amicus Therapeutics Inc |
40.17%
13,257,286
|
$156,170,829,000 | 5.73% |
| Immunome, Inc. |
Opened
4,889,554
|
$120,674,193,000 | 4.43% |
| Scholar Rock Hldg Corp |
88.59%
6,419,610
|
$114,012,274,000 | 4.18% |
| Fate Therapeutics Inc |
1.63%
13,169,057
|
$96,660,878,000 | 3.55% |
| Regenxbio Inc |
127.05%
4,551,556
|
$95,901,285,000 | 3.52% |
| Deciphera Pharmaceuticals In |
270.16%
5,296,643
|
$83,316,194,000 | 3.06% |
| Kymera Therapeutics, Inc. |
33.49%
1,734,089
|
$69,710,378,000 | 2.56% |
| ADC Therapeutics SA |
103.26%
15,269,217
|
$68,558,784,000 | 2.52% |
| Stoke Therapeutics, Inc. |
154.51%
5,073,049
|
$68,486,162,000 | 2.51% |
| Augmedix Inc |
13.91%
16,380,327
|
$66,995,537,000 | 2.46% |
| Nurix Therapeutics, Inc. |
49.10%
4,483,016
|
$65,900,335,000 | 2.42% |
| Biohaven Ltd |
Opened
1,163,241
|
$63,617,650,000 | 2.33% |
| Beam Therapeutics Inc. |
1.61%
1,879,617
|
$62,102,546,000 | 2.28% |
| Zymeworks Inc |
Opened
5,560,798
|
$58,499,595,000 | 2.15% |
| LivaNova PLC |
36.09%
1,037,780
|
$58,053,413,000 | 2.13% |
| Shattuck Labs, Inc. |
0.08%
5,615,489
|
$50,202,472,000 | 1.84% |
| ALX Oncology Holdings Inc. |
464.23%
4,326,509
|
$48,240,575,000 | 1.77% |
| Neurogene Inc |
Opened
935,252
|
$47,604,327,000 | 1.75% |
| Akero Therapeutics Inc |
17.10%
1,858,702
|
$46,950,813,000 | 1.72% |
| Absci Corporation |
2.77%
8,253,316
|
$46,878,835,000 | 1.72% |
| Pliant Therapeutics, Inc. |
0.92%
3,097,220
|
$46,148,578,000 | 1.69% |
| Silence Therapeutics plc |
Opened
2,027,669
|
$43,797,650,000 | 1.61% |
| IDEAYA Biosciences, Inc. |
Opened
922,678
|
$40,487,111,000 | 1.49% |
| 4d Molecular Therapeutics In |
Opened
1,261,427
|
$40,189,064,000 | 1.48% |
| Annexon Inc |
57.09%
5,503,190
|
$39,457,872,000 | 1.45% |
| Boston Scientific Corp. |
Opened
560,926
|
$38,417,822,000 | 1.41% |
| Celldex Therapeutics Inc. |
56.70%
896,454
|
$37,624,174,000 | 1.38% |
| Keros Therapeutics, Inc. |
Opened
552,506
|
$36,575,897,000 | 1.34% |
| Catalent Inc. |
Opened
632,464
|
$35,702,593,000 | 1.31% |
| Immunovant Inc |
Opened
969,621
|
$31,328,455,000 | 1.15% |
| Replimune Group Inc |
2.32%
3,729,983
|
$30,473,961,000 | 1.12% |
| Abbott Labs |
Opened
262,371
|
$29,821,088,000 | 1.09% |
| IGM Biosciences, Inc. |
7.85%
3,072,478
|
$29,649,413,000 | 1.09% |
| Align Technology, Inc. |
Opened
87,255
|
$28,612,660,000 | 1.05% |
| Cogent Biosciences, Inc. |
Opened
3,962,602
|
$26,628,685,000 | 0.98% |
| 89bio Inc |
Opened
2,264,566
|
$26,359,548,000 | 0.97% |
| Cigna Group (The) |
Opened
65,435
|
$23,765,338,000 | 0.87% |
| Evolent Health Inc |
Opened
679,172
|
$22,270,050,000 | 0.82% |
| Verve Therapeutics Inc |
12.49%
1,604,515
|
$21,307,959,000 | 0.78% |
| Entrada Therapeutics Inc |
34.32%
1,283,735
|
$18,190,525,000 | 0.67% |
| HCA Healthcare Inc |
Opened
52,487
|
$17,505,989,000 | 0.64% |
| Elevance Health Inc |
62.82%
31,223
|
$16,190,374,000 | 0.59% |
| Ardelyx Inc |
Opened
2,194,560
|
$16,020,288,000 | 0.59% |
| Boundless Bio Inc |
Opened
1,114,034
|
$15,874,985,000 | 0.58% |
| Stryker Corp. |
Opened
43,246
|
$15,476,446,000 | 0.57% |
| Gritstone Bio Inc |
17.23%
5,755,075
|
$14,790,543,000 | 0.54% |
| Prime Medicine Inc |
Opened
2,074,350
|
$14,520,450,000 | 0.53% |
| Icon Plc |
Opened
36,949
|
$12,413,017,000 | 0.46% |
| Progyny Inc |
Opened
320,864
|
$12,240,962,000 | 0.45% |
| Ventyx Biosciences Inc |
Opened
2,164,126
|
$11,902,693,000 | 0.44% |
| Intuitive Surgical Inc |
Opened
29,546
|
$11,791,513,000 | 0.43% |
| Cytokinetics Inc |
Opened
161,600
|
$11,329,776,000 | 0.42% |
| Quest Diagnostics, Inc. |
Opened
83,849
|
$11,161,140,000 | 0.41% |
| Mckesson Corporation |
Opened
20,707
|
$11,116,553,000 | 0.41% |
| Nuvation Bio Inc |
12.69%
3,031,009
|
$11,032,873,000 | 0.40% |
| Elanco Animal Health Inc |
Opened
676,039
|
$11,005,915,000 | 0.40% |
| Blueprint Medicines Corp |
Opened
113,060
|
$10,724,872,000 | 0.39% |
| Penumbra Inc |
Opened
44,613
|
$9,956,729,000 | 0.37% |
| Repare Therapeutics Inc. |
25.90%
2,016,302
|
$9,496,782,000 | 0.35% |
| Apellis Pharmaceuticals Inc |
Opened
155,000
|
$9,110,900,000 | 0.33% |
| Stereotaxis, Inc. |
122.44%
3,308,798
|
$8,635,963,000 | 0.32% |
| Cabaletta Bio Inc |
36.41%
442,826
|
$7,554,612,000 | 0.28% |
| Lava Therapeutics Nv |
26.34%
2,074,372
|
$6,907,659,000 | 0.25% |
| Atara Biotherapeutics Inc |
48.38%
9,263,309
|
$6,428,736,000 | 0.24% |
| Invivyd Inc |
25.00%
1,440,725
|
$6,396,819,000 | 0.23% |
| RAPT Therapeutics, Inc. |
19.01%
662,398
|
$5,948,334,000 | 0.22% |
| AC Immune SA |
Opened
2,007,031
|
$5,940,812,000 | 0.22% |
| Establishment Labs Holdings Inc |
Opened
114,341
|
$5,819,957,000 | 0.21% |
| Allakos Inc |
35.59%
3,451,076
|
$4,348,356,000 | 0.16% |
| Xeris Biopharma Holdings Inc |
No change
1,046,587
|
$2,312,957,000 | 0.08% |
| Achilles Therapeutics Plc |
No change
1,608,089
|
$2,010,111,000 | 0.07% |
| AlloVir, Inc. |
131.73%
1,907,969
|
$1,440,326,000 | 0.05% |
| Adaptimmune Therapeutics Plc |
Opened
715,607
|
$1,130,659,000 | 0.04% |
| Standard BioTools Inc |
Opened
411,631
|
$1,115,520,000 | 0.04% |
| Hookipa Pharma Inc |
76.68%
1,063,769
|
$757,404,000 | 0.03% |
| Alpha Teknova Inc |
69.80%
171,453
|
$433,776,000 | 0.02% |
| Seagen Inc |
Closed
854,013
|
$151,109,000 | |
| Argenx Se |
Closed
385,818
|
$146,179,000 | |
| Horizon Therapeutics Pub L |
Closed
913,319
|
$72,846,000 | |
| The Beauty Health Company |
Closed
5,186,348
|
$66,696,000 | |
| Centene Corp. |
Closed
651,447
|
$55,119,000 | |
| Xenon Pharmaceuticals Inc |
Closed
1,639,344
|
$49,869,000 | |
| Immunogen, Inc. |
Closed
9,141,045
|
$41,135,000 | |
| Science 37 Holdings Inc |
Closed
19,808,234
|
$39,815,000 | |
| Medavail Holdings Inc |
Closed
25,192,751
|
$38,545,000 | |
| 1Life Healthcare, Inc. |
Closed
4,521,825
|
$35,451,000 | |
| Biomarin Pharmaceutical Inc. |
Closed
300,000
|
$24,861,000 | |
| Oak Str Health Inc |
Closed
1,383,619
|
$22,747,000 | |
| Zymeworks BC Inc |
Closed
3,835,818
|
$20,330,000 | |
| Prothena Corp Plc |
Closed
736,175
|
$19,987,000 | |
| Nevro Corp |
Closed
405,517
|
$17,774,000 | |
| Stevanato Group S.p.A. |
Closed
1,115,825
|
$17,641,000 | |
| IVERIC bio Inc |
Closed
1,518,900
|
$14,612,000 | |
| Jazz Pharmaceuticals plc |
Closed
93,264
|
$14,550,000 | |
| Tandem Diabetes Care Inc |
Closed
187,460
|
$11,096,000 | |
| Somalogic Inc |
Closed
2,088,639
|
$9,441,000 | |
| Invitae Corp |
Closed
3,805,403
|
$9,285,000 | |
| Bioventus Inc |
Closed
1,306,339
|
$8,909,000 | |
| The Oncology Institute Inc |
Closed
1,736,116
|
$8,785,000 | |
| Privia Health Group Inc |
Closed
206,113
|
$6,002,000 | |
| Immatics N.v |
Closed
449,661
|
$3,917,000 | |
| Neoleukin Therapeutics, Inc. |
Closed
3,436,935
|
$3,540,000 | |
| TCR2 Therapeutics Inc. |
Closed
1,094,645
|
$3,174,000 | |
| Atreca Inc |
Closed
800,306
|
$1,433,000 | |
| Sonendo, Inc. |
Closed
498,131
|
$857,000 | |
| Cytosorbents Corp |
Closed
266,365
|
$583,000 | |
| Ayala Pharmaceuticals, Inc. |
Closed
341,030
|
$372,000 | |
| No transactions found | |||
| Showing first 500 out of 108 holdings | |||
Hedge funds similar to Redmile
- Independent Advisor Alliance
- Brighton Jones
- Imc-chicago
- Schwartz Investment Counsel Inc
- Nyl Investors
- Silicon Valley Community Foundation
- Sigfig Wealth Management
- Ritholtz Wealth Management
- Hosking Partners LL.P.
- Carnegie Capital Asset Management
- Hancock Whitney Corp
- Kcm Investment Advisors
- Cohen Klingenstein
- Cambiar Investors